
|Articles|March 15, 2004
Anti-VEGF drug expands options in treating AMD
Las Vegas-The investigational drug pegaptanib sodium (Macugen, Eyetech Pharmaceuticals) has been shown to stabilize and improve vision and showed effectiveness against all three subtypes of lesions involved in wet age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
Neurotrophic keratitis outcomes improve with early, stage-based care
3
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


